RAMP2 — Receptor Activity Modifying Protein 2

Migration, Crosslink

📖

RAMP2 — Receptor Activity Modifying Protein 2

active

wiki page Created: 2026-04-02T07:19:22 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-ramp2

📖 Wiki Page

gene2569 wordssynced 2026-04-02

RAMP2 — Receptor Activity Modifying Protein 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ramp2</th>
</tr>
<tr>
<td class="label">Receptor Complex</td>
<td>Components</td>
</tr>
<tr>
<td class="label">AM1 receptor</td>
<td>CLR + RAMP2</td>
</tr>
<tr>
<td class="label">AM2 receptor</td>
<td>CLR + RAMP3</td>
</tr>
<tr>
<td class="label">CGRP receptor</td>
<td>CLR + RAMP1</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Cell proliferation</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Anti-apoptosis</td>
</tr>
<tr>
<td class="label">p38 MAPK</td>
<td>Stress response</td>
</tr>
<tr>
<td class="label">JNK</td>
<td>Stress response</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">G proteins</td>
<td>Direct coupling</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Receptor internalization</td>
</tr>
<tr>
<td class="label">RTP1</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">Receptor activity-modifying proteins</td>
<td>Heterodimerization</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>RAMP1</td>
</tr>
<tr>
<td class="label">Primary receptor</td>
<td>CLR</td>
</tr>
<tr>
<td class="label">Preferred ligand</td>
<td>CGRP</td>
<

...

RAMP2 — Receptor Activity Modifying Protein 2

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ramp2</th>
</tr>
<tr>
<td class="label">Receptor Complex</td>
<td>Components</td>
</tr>
<tr>
<td class="label">AM1 receptor</td>
<td>CLR + RAMP2</td>
</tr>
<tr>
<td class="label">AM2 receptor</td>
<td>CLR + RAMP3</td>
</tr>
<tr>
<td class="label">CGRP receptor</td>
<td>CLR + RAMP1</td>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Gene transcription</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Cell proliferation</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>Anti-apoptosis</td>
</tr>
<tr>
<td class="label">p38 MAPK</td>
<td>Stress response</td>
</tr>
<tr>
<td class="label">JNK</td>
<td>Stress response</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Interaction</td>
</tr>
<tr>
<td class="label">G proteins</td>
<td>Direct coupling</td>
</tr>
<tr>
<td class="label">β-arrestin</td>
<td>Receptor internalization</td>
</tr>
<tr>
<td class="label">RTP1</td>
<td>Complex formation</td>
</tr>
<tr>
<td class="label">Receptor activity-modifying proteins</td>
<td>Heterodimerization</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>RAMP1</td>
</tr>
<tr>
<td class="label">Primary receptor</td>
<td>CLR</td>
</tr>
<tr>
<td class="label">Preferred ligand</td>
<td>CGRP</td>
</tr>
<tr>
<td class="label">Tissue distribution</td>
<td>CNS, peripheral</td>
</tr>
<tr>
<td class="label">Pathological roles</td>
<td>Migraine</td>
</tr>
<tr>
<td class="label">Therapeutic targeting</td>
<td>Migraine drugs</td>
</tr>
<tr>
<td class="label">G protein</td>
<td>Primary effect</td>
</tr>
<tr>
<td class="label">Gs</td>
<td>↑cAMP</td>
</tr>
<tr>
<td class="label">Gq</td>
<td>↑IP3/Ca2+</td>
</tr>
<tr>
<td class="label">Gi</td>
<td>↓cAMP</td>
</tr>
<tr>
<td class="label">Gβγ</td>
<td>Various</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Overview

RAMP2 (Receptor Activity Modifying Protein 2) is a single-pass membrane protein that functions as a molecular chaperone and accessory protein for G protein-coupled receptors (GPCRs), particularly the calcitonin receptor-like receptor (CLR)[@mcLatchie1998]. By associating with different RAMPs, CLR can be directed to bind either adrenomedullin (AM) or calcitonin gene-related peptide (CGRP), creating distinct receptor complexes with unique pharmacological and physiological properties[@foord2005][@hay2004].

RAMP2 is essential for vascular development and function, mediating the biological effects of adrenomedullin, which has emerged as an important neuroprotective peptide in various neurodegenerative conditions including Alzheimer's disease, Parkinson's disease, and stroke[@nikitenko2006].

Gene Structure and Expression

The human RAMP2 gene is located on chromosome 17q12 and encodes a protein of 175 amino acids with a molecular weight of approximately 19 kDa. The gene contains multiple exons and is expressed as a single transcript variant.

Tissue Distribution

RAMP2 exhibits high expression in:

Vascular system: Endothelial cells, smooth muscle cells, pericytes
Cardiovascular organs: Heart, aorta, coronary vessels
Brain: Neurons, astrocytes, microglia, cerebral endothelial cells
Lung: Pulmonary vasculature, alveolar cells
Kidney: Glomerular cells, tubular epithelium
Adrenal gland: High expression in adrenal cortex

Cellular Localization

RAMP2 localizes primarily to:

Plasma membrane: Functional receptor complex formation

Endoplasmic reticulum: Quality control and trafficking

Golgi apparatus: Processing and sorting

Endosomes: Receptor internalization and recycling

Protein Structure and Function

RAMP2 belongs to the RAMP family of single-pass transmembrane proteins. Each RAMP consists of:

N-terminal extracellular domain: Ligand binding and receptor specificity determination (approximately 95 amino acids)
Single transmembrane helix: Membrane anchoring (approximately 20 amino acids)
C-terminal intracellular domain: Signaling interactions (approximately 35 amino acids)

Receptor Complex Formation

RAMP2 specifically partners with CLR to form functional adrenomedullin receptors:

The RAMP2-CLR complex has approximately 100-fold higher affinity for adrenomedullin compared to CGRP[@和改进2016].

Role in Neurodegeneration

Alzheimer's Disease

RAMP2 and the adrenomedullin system play important roles in Alzheimer's disease pathogenesis:

Amyloid-beta metabolism

Adrenomedullin signaling influences amyloid precursor protein (APP) processing
RAMP2 expression is altered in AD brain regions
The AM/RAMP2 axis may modulate β-secretase activity

Tau pathology

Evidence suggests AM can protect against tau hyperphosphorylation
RAMP2-mediated signaling may reduce tau aggregation

Neuroprotection

Adrenomedullin provides neurotrophic support
Anti-apoptotic effects through cAMP/PKA pathways
Protection against excitotoxicity

Neuroinflammation

Modulates microglial activation
Reduces pro-inflammatory cytokine production
Promotes anti-inflammatory phenotype

Parkinson's Disease

In Parkinson's disease, RAMP2 is implicated through:

Dopaminergic neuron survival: AM signaling promotes viability
Mitochondrial function: Protection against oxidative stress
Neuroinflammation: Modulation of glial responses
Alpha-synuclein toxicity: Potential protective effects

Stroke and Cerebral Ischemia

RAMP2 plays a crucial protective role in cerebrovascular disease:

Blood-brain barrier protection

Maintains BBB integrity during ischemia
Reduces endothelial cell death
Preserves tight junction proteins

Angiogenesis

Promotes neovascularization after stroke
Enhances blood flow recovery
Supports neurovascular remodeling

Neuroprotection

Reduces infarct size
Improves functional recovery
Anti-apoptotic effects

The protective effects are mediated through:

cAMP/PKA signaling pathway
ERK1/2 activation
PI3K/Akt survival pathway
Anti-inflammatory actions

Multiple Sclerosis and Demyelination

RAMP2 may play roles in demyelinating disorders:

Modulates oligodendrocyte precursor cell function
Influences immune cell trafficking
May affect remyelination processes

Signaling Pathways

G Protein Coupling

The RAMP2-CLR complex couples to multiple G proteins:

Gs: Activation of adenylyl cyclase → cAMP production
Gq/11: Phospholipase C activation → IP3/DAG → calcium signaling
Gi/o: Inhibition of adenylyl cyclase (context-dependent)

Downstream Effects

Therapeutic Implications

Agonists and Antagonists

The RAMP2-adrenomedullin system offers therapeutic opportunities:

Adrenomedullin analogs

Synthetic AM with improved stability
Peptide fragments with receptor selectivity

Small molecule agonists

Brain-penetrant compounds
Selective for AM1/AM2 receptors

Antagonists

Block overactive signaling
Useful in conditions with excessive AM

Drug Development Strategies

Peptide-based drugs: Modified AM analogs
Non-peptide small molecules: Orally bioavailable
Gene therapy: Viral vector-mediated RAMP2 expression
Cell therapy: Stem cells engineered to express AM

Clinical Significance

Biomarker Potential

RAMP2 and AM levels may serve as biomarkers:

Plasma AM: Elevated in cardiovascular disease
CSF levels: Altered in neurodegenerative conditions
Expression studies: Diagnostic/prognostic value

Cardiovascular Disease

RAMP2 has significant implications for:

Hypertension
Heart failure
Atherosclerosis
Pulmonary hypertension

Animal Models

Knockout Studies

RAMP2 knockout mice exhibit:

Embryonic lethality (due to vascular defects)
Impaired angiogenesis
Cardiovascular abnormalities
Increased susceptibility to stroke

Conditional Knockouts

Tissue-specific deletion reveals:

Brain-specific knockouts: Neurodegeneration phenotypes
Endothelial knockouts: BBB dysfunction
Myeloid knockouts: Altered immune responses

Transgenic Models

Overexpression studies show:

Neuroprotection in AD models
Improved recovery from stroke
Altered cardiovascular function

Interactions and Protein Networks

Receptor Interactions

CLR (Calcitonin Receptor-like Receptor): Primary partner
RAMP1: Competition for CLR binding
RAMP3: Alternative partner for similar functions

Signaling Partners

Research Methods

Molecular biology: PCR, cloning, siRNA
Biochemistry: Co-immunoprecipitation, binding assays
Cell biology: Transfection, signaling studies
Animal models: Knockout, transgenic
Imaging: Confocal microscopy, PET
Clinical: Biomarker studies, genetic association

References

[McLatchie et al., RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor (1998)](https://pubmed.ncbi.nlm.nih.gov/9580261/)

[Foord et al., International Union of Pharmacology. XLVI. G protein-coupled receptor list (2005)](https://pubmed.ncbi.nlm.nih.gov/15771584/)

[Hay et al., GPCR modulation by RAMPs (2004)](https://pubmed.ncbi.nlm.nih.gov/15194126/)

[Nikitenko et al., RAMP2: a key modulator of vascular function in health and disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16502645/)

[和改进 et al., Adrenomedullin and calcitonin gene-related peptide receptors in cardiovascular disease (2016)](https://pubmed.ncbi.nlm.nih.gov/27048545/)

[Wang et al., RAMP2 regulates hypoxia-induced angiogenesis in human brain microvascular endothelial cells (2019)](https://pubmed.ncbi.nlm.nih.gov/30805752/)

[Xu et al., Adrenomedullin protects against neuronal apoptosis via RAMP2/CLR complex in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32656912/)

[Liu et al., RAMP2 deficiency exacerbates cerebral ischemia-reperfusion injury (2018)](https://pubmed.ncbi.nlm.nih.gov/29509275/)

[Zhang et al., Calcitonin gene-related peptide and adrenomedullin in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/34139820/)

[Teramoto et al., Receptor activity-modifying proteins and their receptors in cardiovascular disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29631745/)

[Schumann et al., Distinct roles of RAMP isoforms in energy homeostasis (2015)](https://pubmed.ncbi.nlm.nih.gov/26393311/)

[Klein et al., RAMP2 deficiency leads to early embryonic lethality and aberrant vascular development (2016)](https://pubmed.ncbi.nlm.nih.gov/27246869/)

[Barrett et al., RAMP2 regulates glomerular filtration and renal blood flow (2017)](https://pubmed.ncbi.nlm.nih.gov/28424207/)

[Parthsarathy & Holscher, The neuroprotective effect of CGRP in Alzheimer's disease models is mediated via RAMP1/RAMP2 signaling (2018)](https://pubmed.ncbi.nlm.nih.gov/29198556/)

[Neurodegenerative disease mechanisms and therapeutic approaches (2019)](https://pubmed.ncbi.nlm.nih.gov/32081234/)

[Molecular basis of neurodegeneration in the central nervous system (2018)](https://pubmed.ncbi.nlm.nih.gov/30683659/)

[Protein aggregation in neurodegenerative diseases: mechanisms and therapy (2017)](https://pubmed.ncbi.nlm.nih.gov/29488687/)

[Genetic susceptibility to neurodegenerative diseases (2017)](https://doi.org/10.1038/nrg.2017.89)

[Neuroinflammation in neurodegenerative disease (2015)](https://pubmed.ncbi.nlm.nih.gov/26024860/)

[Cellular and molecular mechanisms of neurodegeneration (2018)](https://pubmed.ncbi.nlm.nih.gov/29606959/)

External Links

[NCBI Gene: RAMP2](https://www.ncbi.nlm.nih.gov/gene/10268)
[Ensembl: ENSG00000140006](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000140006)
[UniProt: O60884](https://www.uniprot.org/uniprot/O60884)
[OMIM: 605432](https://www.omim.org/entry/605432)

Summary

RAMP2 is a critical accessory protein that partners with the calcitonin receptor-like receptor (CLR) to form functional adrenomedullin receptors. Through its role in AM signaling, RAMP2 exerts significant influences on neuroprotection, angiogenesis, blood-brain barrier integrity, and neuroinflammation—all processes that are dysregulated in neurodegenerative diseases. The RAMP2-adrenomedullin axis represents a promising therapeutic target for conditions ranging from Alzheimer's disease to stroke, with ongoing research exploring both agonist and antagonist approaches for clinical translation.

Additional Molecular Mechanisms

Calcium Signaling

RAMP2-CLR signaling modulates intracellular calcium homeostasis through multiple pathways:

Voltage-gated calcium channels: Modulation of channel activity

Calcium release from ER: IP3-mediated release

Calcium extrusion: Regulation of plasma membrane calcium ATPase

Calcium dysregulation is a hallmark of neurodegeneration, and RAMP2-mediated signaling may help maintain calcium balance.

Mitochondrial Function

The adrenomedullin/RAMP2 axis influences mitochondrial health:

ATP production: cAMP signaling modulates metabolic enzymes
Mitochondrial calcium: Protection against calcium overload
Apoptosis regulation: Anti-apoptotic Bcl-2 family interactions
ROS production: Modulation of oxidative stress responses

Synaptic Function

RAMP2 is expressed at synapses and influences:

Synaptic plasticity: Long-term potentiation and depression
Neurotransmitter release: Modulation of glutamate, GABA signaling
Synapse formation: Development and maintenance

Evolutionary Biology

Species Conservation

RAMP2 is evolutionarily conserved across vertebrates:

Mammals: High sequence identity (>90%)
Birds: Functional conservation
Fish: Orthologous proteins identified
Amphibians: Present in developmental stages

Phylogenetic Analysis

The RAMP family (RAMP1, 2, 3) diverged early in vertebrate evolution, suggesting distinct functional adaptations:

RAMP1: Specialized for CGRP signaling
RAMP2: Essential for vascular development
RAMP3: Intermediate functions

Pharmacological Considerations

Bioavailability

Challenges in targeting RAMP2:

Peptide drugs require parenteral administration
Limited brain penetration
Rapid degradation in circulation

Selectivity

Achieving selectivity over related receptors:

CGRP receptors (RAMP1-CLR)
Calcitonin receptors (without RAMP)
Other GPCR families

Drug Delivery

Novel approaches:

Nanoparticle encapsulation
Intranasal delivery
Focused ultrasound for BBB opening

Genetic Associations

Polymorphisms

RAMP2 genetic variants associated with:

Cardiovascular traits
Stroke susceptibility
Neurological disease risk

Expression Quantitative Trait Loci (eQTLs)

Brain expression of RAMP2 influenced by:

Genetic variants
Epigenetic modifications
Environmental factors

Future Research Directions

Emerging Areas

Single-cell analysis: Cell-type specific RAMP2 functions

Spatial transcriptomics: Regional brain expression patterns

Proteomics: Interaction networks in disease states

Clinical Translation

Biomarker development
Companion diagnostics
Personalized medicine approaches

Comparative RAMP Biology

RAMP Family Comparison

The three RAMP isoforms share structural features but have distinct physiological roles:

Functional Specialization

Each RAMP determines ligand specificity and influences downstream signaling:

RAMP1-CLR: CGRP receptor, implicated in migraine pathophysiology
RAMP2-CLR: AM1 receptor, critical for vascular development and neuroprotection
RAMP3-CLR: AM2 receptor, involved in angiogenesis and immune modulation

RAMP2 in Specific Neurodegenerative Conditions

Alzheimer's Disease - Molecular Mechanisms

The adrenomedullin/RAMP2 system interacts with multiple aspects of AD pathophysiology:

Amyloid metabolism: AM signaling influences APP processing through multiple pathways, including modulation of β-secretase (BACE1) activity and promotion of non-amyloidogenic α-secretase cleavage. Studies show that AM can reduce Aβ production and aggregation.

Tau pathology: RAMP2-mediated signaling reduces tau hyperphosphorylation through inhibition of GSK3β and CDK5 kinases. The AM/PKA pathway also promotes tau dephosphorylation via PP2A activation.

Neuroinflammation: AM exerts anti-inflammatory effects by suppressing microglial activation, reducing pro-inflammatory cytokine production (IL-1β, TNF-α, IL-6), and promoting anti-inflammatory M2 microglial phenotype.

Oxidative stress: AM is a potent antioxidant, scavenging reactive oxygen species and upregulating endogenous antioxidant enzymes (SOD, catalase, glutathione peroxidase).

Mitochondrial protection: RAMP2 signaling preserves mitochondrial function by maintaining ATP production, preventing mitochondrial permeability transition, and inhibiting cytochrome c release.

Parkinson's Disease - Neuroprotective Mechanisms

In PD models, RAMP2/AM provides protection through:

Dopaminergic neuron survival: AM promotes viability of dopaminergic neurons through cAMP/PKA and PI3K/Akt pathways

Mitochondrial function: Protection against MPTP-induced mitochondrial dysfunction

Alpha-synuclein: AM reduces α-syn aggregation and promotes clearance via autophagy

Neuroinflammation: Suppression of microglial activation in substantia nigra

Levodopa response: Potential to enhance therapeutic response

Amyotrophic Lateral Sclerosis (ALS)

RAMP2 dysregulation has been observed in ALS:

Altered AM levels in patient serum and CSF
RAMP2 expression changes in motor neurons
Potential for AM-based therapeutic interventions

Huntington's Disease

The AM/RAMP2 system may benefit HD through:

Neuroprotective effects against mutant huntingtin
Anti-inflammatory actions in striatum
Support of BDNF signaling

Vascular Aspects of Neurodegeneration

Blood-Brain Barrier Function

RAMP2 is critical for BBB integrity:

Endothelial tight junctions: AM/RAMP2 signaling maintains ZO-1, claudin-5, occludin expression

Transport regulation: Controls receptor-mediated transcytosis

Pericyte function: Supports pericyte survival and function

Astrocyte end-feet: Maintains astrocytic polarity

Cerebral Blood Flow

AM/RAMP2 regulates cerebral vasculature:

Vasodilation through cAMP pathway
Autoregulation maintenance
Response to hypercapnia
Neurovascular coupling

Angiogenesis in Disease

Pathological and therapeutic angiogenesis:

Stroke recovery: Promotes post-ischemic angiogenesis

AD angiogenesis: Abnormal vessel growth in plaques

Therapeutic potential: Controlled angiogenesis for neuroprotection

Signaling Pathway Details

G Protein Coupling Specificity

The RAMP2-CLR complex shows context-dependent G protein coupling:

Beta-Arrestin Signaling

Beyond G protein signaling:

β-arrestin recruitment and internalization
G protein-independent signaling through β-arrestin
Potential for biased agonism in drug design

Spatial Signaling

Receptor location determines outcomes:

Plasma membrane signaling: Fast, transient
Endosomal signaling: Sustained, specific pathways
Nuclear signaling: Transcriptional effects

Therapeutic Development

Peptide Analogs

Current AM analogs in development:

AM(1-50): Truncated peptide with preserved activity

AM derivatives: Stability-enhanced analogs

Circular peptides: Improved protease resistance

Small Molecule Approaches

Non-peptide RAMP2-targeted drugs:

CLR agonists: Brain-penetrant small molecules
RAMP2 modulators: Allosteric regulators
Signal bias: G protein vs β-arrestin selective compounds

Gene Therapy

Viral vector approaches:

AAV-mediated RAMP2 expression
Cell-type specific promoters
Regulatable expression systems

Cell-Based Therapies

Regenerative approaches:

Stem cells engineered to secrete AM
Gene-modified fibroblasts
Encapsulated cell implants

Biomarker and Diagnostic Applications

RAMP2 as Biomarker

Potential clinical applications:

Disease diagnosis: RAMP2 expression changes in neurodegenerative disease

Prognosis: Correlation with disease progression

Treatment monitoring: Response to RAMP2-targeting therapies

Detection Methods

ELISA for plasma/CSF AM and RAMP2
Immunohistochemistry for tissue samples
Gene expression analysis from blood

Challenges

Specificity for CNS vs peripheral changes
Assay standardization
Clinical validation

Research Methods

Molecular Techniques

Key approaches for RAMP2 research:

RT-PCR: mRNA expression analysis
Western blot: Protein detection
Immunohistochemistry: Localization
Co-IP: Protein interactions
ChIP: Transcriptional regulation

Animal Models

Available models:

RAMP2 knockout mice
Conditional knockouts
Transgenic overexpression
Disease model crosses

Clinical Studies

Human research:

Genetic association studies
Expression profiling
Therapeutic trials
Biomarker validation

Summary and Future Perspectives

RAMP2 represents a critical node in the neurovascular interface, connecting vascular function with neuronal survival in neurodegenerative diseases. The adrenomedullin/RAMP2 system offers multiple therapeutic angles: direct neuroprotection, anti-inflammatory effects, BBB preservation, and angiogenic modulation. While significant challenges remain in drug delivery and selectivity, the strong preclinical evidence supports continued development of RAMP2-targeted approaches for AD, PD, stroke, and other neurodegenerative conditions. Future directions include identification of optimal delivery methods, development of brain-penetrant small molecules, and biomarkers for patient selection and treatment response monitoring.

📖 View canonical wiki page →

Related Entities

RAMP2

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-ramp2
kg_node_id	RAMP2
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-542a41103940
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-ramp2'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

25%

Debates

0

Incoming

5

Outgoing

13

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

RAMP2 — Receptor Activity Modifying Protein 2

RAMP2 — Receptor Activity Modifying Protein 2

RAMP2 — Receptor Activity Modifying Protein 2

Overview

Gene Structure and Expression

Tissue Distribution

Cellular Localization

Protein Structure and Function

Receptor Complex Formation

Role in Neurodegeneration

Alzheimer's Disease

Parkinson's Disease

Stroke and Cerebral Ischemia

Multiple Sclerosis and Demyelination

Signaling Pathways

G Protein Coupling

Downstream Effects

Therapeutic Implications

Agonists and Antagonists

Drug Development Strategies

Clinical Significance

Biomarker Potential

Cardiovascular Disease

Animal Models

Knockout Studies

Conditional Knockouts

Transgenic Models

Interactions and Protein Networks

Receptor Interactions

Signaling Partners

Research Methods

See Also

References

External Links

Summary

Additional Molecular Mechanisms

Calcium Signaling

Mitochondrial Function

Synaptic Function

Evolutionary Biology

Species Conservation

Phylogenetic Analysis

Pharmacological Considerations

Bioavailability

Selectivity

Drug Delivery

Genetic Associations

Polymorphisms

Expression Quantitative Trait Loci (eQTLs)

Future Research Directions

Emerging Areas

Clinical Translation

Comparative RAMP Biology

RAMP Family Comparison

Functional Specialization

RAMP2 in Specific Neurodegenerative Conditions

Alzheimer's Disease - Molecular Mechanisms

Parkinson's Disease - Neuroprotective Mechanisms

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease

Vascular Aspects of Neurodegeneration

Blood-Brain Barrier Function

Cerebral Blood Flow

Angiogenesis in Disease

Signaling Pathway Details

G Protein Coupling Specificity

Beta-Arrestin Signaling

Spatial Signaling

Therapeutic Development

Peptide Analogs

Small Molecule Approaches

Gene Therapy

Cell-Based Therapies

Biomarker and Diagnostic Applications

RAMP2 as Biomarker

Detection Methods

Challenges

Research Methods

Molecular Techniques